OrthoPediatrics announced its continued support of the 2023 Pediatric Orthopaedic Society of North America annual meeting this week in Nashville, Tennessee. At the Annual Meeting the Company highlighted its growing portfolio of pediatric-specific solutions at its exhibit booth. The Company sponsored a sub-specialty session focused on hip dysplasia in pediatric patients. This session covered two extreme and regularly occurring situations, including stable dysplasia in infants as well as severe dysplasia and degeneration in adolescents. Additionally, the Company highlighted progress with the ApiFix non-fusion technology, hosting a workshop for current users of the system to share their experiences and best-practice, as well as discuss positive one-year ApiFix follow-up clinical data from 54 patients in the registry who are over one-year post surgery. OrthoPediatrics has established a longer-term commitment to POSNA deepening its commitment to providing ongoing support of specialty symposiums and awarding educational grants and scholarships to attendees. The Company has elevated its sponsorship level and is now the only Emerald Sponsor of the organization.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KIDS:
- OrthoPediatrics Corp. Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
- KIDS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- OrthoPediatrics Corp. Announces Launch of RESPONSE™ 5.5/6.0 Cannulated Screw System
- OrthoPediatrics price target raised to $57 from $53 at Truist
- OrthoPediatrics Corp. to Report First Quarter 2022 Financial Results on May 2, 2023